NCT06017297 2024-11-12
ESR-22-21719
Georgetown University
Phase 2 Withdrawn
Clinical Trials
21 trialsNCT05514912 2023-12-26
Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial
Emory University
Phase 2 Withdrawn
NCT04546828 2022-06-15
A Single-arm Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk IHCC in Korea
Samsung Medical Center
Phase 2 Withdrawn
NCT04796454 2022-06-01
PAMICC
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Withdrawn
NCT04625543 2022-04-26
Neoadjuvant Immunotherapy to ESCC
Qilu Hospital of Shandong University
Phase 2 Withdrawn
NCT04480190 2022-04-20
Neoadjuvant Therapy in Biliary Adenocarcinoma
University of Cincinnati
Phase 1 Withdrawn
NCT04859582 2021-12-16
KEYNOTE-859
Merck Sharp & Dohme LLC
Phase 3 Withdrawn
NCT02272699 2021-03-18
Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma
Peking University
Phase 2/3 Withdrawn
NCT03579758 2020-06-05
Chemotherapy Before & After Surgery in Patients With Resectable Gallbladder Cancer
Emory University
Phase 3 Withdrawn
NCT03881111 2020-02-11
KEYNOTE-590
Merck Sharp & Dohme LLC
Phase 3 Withdrawn
NCT03697239 2019-06-11
High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
University of California, San Diego
Phase 1/2 Withdrawn
NCT03797443 2019-05-31
High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
Piedmont Cancer Institute
Phase 1/2 Withdrawn
NCT03908333 2019-05-30
High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
Medical College of Wisconsin
Phase 1/2 Withdrawn
NCT03392571 2019-05-07
Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients
Pancreatic Cancer Research Team
Phase 2 Withdrawn
NCT03081039 2018-02-19
A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablation Intra-Hepatic Cholangiocarcinoma
University of Louisville
Phase 3 Withdrawn
NCT02856568 2017-05-30
Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma
Mayo Clinic
Phase 1 Withdrawn
NCT01857726 2016-04-28
Comparison of TACE Versus TACE/TACI Combination in Advanced Hepatocellular Carcinoma With Portal Vein Invasion
Seoul National University Hospital
Phase NA Withdrawn
NCT00746655 2015-12-24
SBRT + TACE for Primary Hepatocellular Carcinoma
University of Pittsburgh
Phase NA Withdrawn
NCT01998347 2015-11-20
Paclitaxel Liposome and Cisplatin as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer
Shantou University Medical College
Phase 3 Withdrawn
NCT00808145 2014-10-22
Study of Sorafenib, Gemcitabine, and Cisplatin in Advanced Hepatocellular Carcinoma (HCC)
Lahey Clinic
Phase 2 Withdrawn
NCT01327521 2012-06-11
Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma
Stanford University
Phase 3 Withdrawn